Tenderwize
Retour à la recherche

Open House Originale Rabattverträge 2025-31 - Doravirin

Techniker Krankenkasse·Hamburg, Germany·Deadline Nov 29, 2027 · 460 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-31 - Doravirin

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

20 / 100

Facteurs de risque

No estimated contract value, discount rates, or volume commitments. Financial attractiveness unknown.

Contract ends automatically upon patent expiry; if Doravirin patent expires before 30.11.2027, the contract terminates...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Nov 2027
  • Supply of Doravirin pharmaceutical products under discount contracts (Rabattverträge) according to § 130c SGB V.
  • Open House procedure – any eligible pharmaceutical undertaker may join during the contract term.
Afficher le résumé complet

Open House procedure by Techniker Krankenkasse to conclude discount contracts for the active substance Doravirin. No competition; any eligible pharmaceutical undertaker can join during the contract term (max 24 months, ending 30.11.2027). No estimated value available. No procurement documents analyzed beyond the notice. Notably, the structured data indicates EU funding while the XML notice states no EU funding.

Risques

No estimated contract value, discount rates, or volume commitments. Financial attractiveness unknown.

Contract ends automatically upon patent expiry; if Doravirin patent expires before 30.11.2027, the contract terminates...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical undertaker (pharmazeutischer Unternehmer) as per § 4 Abs. 18 AMG for the offered medicinal product.
  • Must have valid marketing authorization for Doravirin in Germany or be entitled to place the product on the market.

Eligibility

  • Must submit a self-declaration (Anlage 4) confirming eligibility and reliability.

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria applicable.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open House Originale Rabattverträge 2025-31 - Doravirin

Discount contracts for Doravirin. The TK aims to conclude contracts with all suitable pharmaceutical undertakers. No individual negotiations, uniform conditions, non-exclusive. Max 24 months from 01.12.2025 to 30.11.2027. Early termination upon patent expiry.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Nov 2025 - Nov 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria applicable.

Date limite

Deadline Nov 29, 2027

Détails de la procédure

Date de publication
12 Oct 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
669486-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3